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SCIENTIFIC OPINION  
Scientific Opinion on an application (EFSA-GMO-NL-2012-107) for the 
placing on the market of maize MON 810 pollen under Regulation (EC) No 
1829/2003 from Monsanto
1
 
EFSA Panel on Genetically Modified Organisms (GMO)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
In this opinion, the EFSA GMO Panel addresses the safety of maize MON 810 pollen to complete the scope of 
an application (RX-MON 810) for the marketing of genetically modified maize MON 810 with the use of 
MON 810 pollen as or in food. Data on molecular characterisation of maize MON 810 did not raise any safety 
concerns with respect to its pollen. The EFSA GMO Panel has previously assessed the safety of the newly 
expressed Cry1Ab protein in maize MON 810. The assessment and conclusions of the GMO Panel on the safety 
of this protein, including its potential toxicity and allergenicity, also apply to the Cry1Ab protein expressed in 
MON 810 pollen. While the EFSA GMO Panel is not in a position to conclude on the safety of maize pollen in 
or as food in general, it concludes that the genetic modification in maize MON 810 does not constitute an 
additional health risk if maize MON 810 pollen is to replace maize pollen from non-GM maize in or as food. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following the submission of an application (EFSA-GMO-NL-2012-107) under Regulation (EC) 
No 1829/2003 from Monsanto, the Panel on Genetically Modified Organisms of the European Food 
Safety Authority (EFSA GMO Panel) was asked to deliver a scientific opinion on the safety of the 
genetically modified (GM) maize MON 810 pollen as or in food. 
In delivering its scientific opinion, the EFSA GMO Panel considered the application EFSA-GMO-
NL-2012-107, other applications related to maize MON 810 submitted in the European Union (EU), 
scientific comments submitted by the Member States and relevant scientific publications.  
The molecular characterisation data established that maize MON 810 expresses the Cry1Ab 
insecticidal protein under the control of enhanced 35S promoter from Cauliflower mosaic virus and 
incorporates the maize Hsp70 intron. Bioinformatic analysis of the open reading frames spanning the 
junctions between the inserted DNA and maize genomic DNA did not raise safety concerns. The 
stability of the inserted DNA was confirmed over several generations, implying that the integrity of 
the insert was maintained throughout microsporogenesis and pollen production. Analyses of the levels 
of newly expressed proteins in various plant tissues did not raise safety concerns. Levels of Cry1Ab in 
pollen were undetectable or lower than levels observed in maize MON 810 grain and forage. 
With regards to the newly expressed Cry1Ab protein, the results of the molecular characterisation 
indicate that the same Cry1Ab protein is expressed in pollen as in other parts of the plant. Therefore, 
the assessment and conclusions reached by the GMO Panel on the safety of the protein Cry1Ab, 
including its potential toxicity and allergenicity, for food/feed aspects also apply to pollen.  
While limited data are available on the compositional and safety characteristics of maize pollen in 
general and pollen of maize MON 810 in particular, the EFSA GMO Panel considered a range of 
additional data constituting a weight of evidence approach for the safety of maize MON 810 pollen 
compared with other maize pollen. These data consist of (1) the above-mentioned molecular 
characterisation of maize MON 810; (2) extensive data on composition and agronomic/phenotypic 
characteristics in maize MON810, including reproductive traits related to pollen production and 
viability; and (3) the food and feed safety of maize MON 810 and the newly expressed Cry1Ab 
protein. These data do not indicate potential concerns over the safety of the newly expressed Cry1Ab 
protein or the occurrence of unintended effects that could raise safety concerns.  
While the EFSA GMO Panel is not in a position to conclude on the safety of maize pollen occurring 
in or as food in general, it concludes that the genetic modification in maize MON 810 does not 
constitute an additional health risk if maize MON 810 pollen were to replace maize pollen from non-
GM maize in or as food. 
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BACKGROUND  
On 12 March 2012, the European Food Safety Authority (EFSA) received from the Competent 
Authority of the Netherlands an application (Reference EFSA-GMO-NL-2012-107), for authorisation 
of maize MON 810 (Unique Identifier MON-ØØ81Ø-6) pollen, submitted by Monsanto within the 
framework of Regulation (EC) No 1829/2003 on GM food and feed.
4
 After having received the 
application EFSA-GMO-NL-2012-107 and in accordance with Article 5(2)(b) of Regulation (EC) No 
1829/2003, EFSA informed Member States and the European Commission, and made the summary of 
the application available to the public on the EFSA website. EFSA initiated a formal review of the 
application to check compliance with the requirements laid down in Articles 5(3) of Regulation (EC) 
No 1829/2003. On 29 May 2012, EFSA declared the application as formally valid in accordance with 
Articles 6(1) of Regulation (EC) No 1829/2003. 
EFSA made the valid application available to Member States and the European Commission, and 
consulted nominated risk assessment bodies of Member States, including national Competent 
Authorities within the meaning of Directive 2001/18/EC
5
 following the requirements of Article 6(4) of 
Regulation (EC) No 1829/2003, to request their scientific opinion. Member State bodies had three 
months after the date of receipt of the valid application (until 28 August 2012) within which to make 
their opinion known. 
The EFSA Scientific Panel on Genetically Modified Organisms (EFSA GMO Panel) carried out an 
evaluation of the scientific risk assessment of the maize MON 810 pollen as or in food, in accordance 
with Article 6(6) of Regulation (EC) No 1829/2003. When carrying out the safety evaluation, the 
EFSA GMO Panel took into account the principles described in its risk assessment and monitoring 
guidelines (EFSA, 2006, 2011a), other applications related to maize MON 810 submitted in the 
European Union (EU) and the scientific comments of the Member States. 
In giving its Scientific Opinion on maize MON 810 pollen to the European Commission, the Member 
States and the applicant in accordance with Article 6(1) of Regulation (EC) No 1829/2003, EFSA has 
endeavoured to respect a time limit of six months from the acknowledgement of the valid application.  
According to Regulation (EC) No 1829/2003, this Scientific Opinion is to be seen as the report 
requested under Article 6(6) of that Regulation and thus will be part of the EFSA overall opinion in 
accordance with Article 6(5). 
TERMS OF REFERENCE  
The EFSA GMO Panel was requested to carry out a scientific risk assessment of maize MON 810 
pollen as or in food in accordance with Article 6(6) of Regulation (EC) No 1829/2003. Where 
applicable, any conditions or restrictions which should be imposed on the placing on the market and/or 
specific conditions or restrictions for use and handling, including post-market monitoring requirements 
based on the outcome of the risk assessment and, in the case of GMOs or food/feed containing or 
consisting of GMOs, conditions for the protection of particular ecosystems/environment and/or 
geographical areas should be indicated in accordance with Article 6(5)(e) of Regulation (EC) No 
1829/2003.  
The EFSA GMO Panel was not requested to give a Scientific Opinion on information required under 
Annex II to the Cartagena Protocol, nor on the proposals for labelling and methods of detection 
(including sampling and the identification of the specific transformation event in the food/feed and/or 
food/feed produced from it), which are matters related to risk management. 
                                                     
4  Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically 
modified food and feed (OJ L 268, 18/10/2003, pp. 1–2). 
5  Directive 20010/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release of 
genetically modified organisms and repealing Council Directive 90/220/EEC (OJ L 106, 17/04/2001, pp. 1–38). 
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1. Introduction 
Maize MON 810 is intended to be cultivated and used like any conventional maize in the EU. This 
opinion covers the possible consequences of the substitution of pollen of maize origin with pollen of 
maize MON 810 and does not consider the safety of pollen per se. 
Most consumers are known to be exposed to pollen via consumption of honey containing pollen 
collected by bees. A high intake of honey, corresponding to 50 g per person per day (JECFA, 2008; 
EFSA, 2011b) corresponds to an intake of 190 mg of maize pollen per individual, or 3.2 mg pollen per 
kilogram body weight for an individual weighing 60 kg (EFSA, 2011c).  
A higher intake may result from the use of pollen pellets as food supplements which may lead to 
exposures as high as 36 g per person per day for adults.  
The evaluation of the risk assessment presented here is based on the information provided in the 
application relating to maize MON 810 pollen, including issues raised by the Member States (see 
Annex G), other applications related to maize MON 810 submitted in the European Union (EU) and 
other relevant scientific publications. 
ASSESSMENT 
Maize MON 810 has been developed to provide protection against certain lepidopteran target pests, 
such as the European corn borer (Ostrinia nubilalis), and species belonging to the genus Sesamia (in 
particular the Mediterranean corn borer (Sesamia nonagrioides)), by the introduction of a truncated 
Bacillus thuringiensis (Bt) gene encoding the insecticidal Cry1Ab protein. 
2. Expression of Cry1Ab in pollen 
Maize MON 810 expresses the insecticidal protein Cry1Ab under the control of enhanced 35S 
promoter from Cauliflower mosaic virus. Stability of the single MON 810 insert over three 
generations was established by Southern analyses, implying that the integrity of the insert was 
maintained throughout microsporogenesis and pollen production (EFSA, 2009a).  
In field trials carried out in 1994 and 1995 in the USA, France and Italy, the levels of Cry1Ab in 
pollen ranged from undetectable to 0.097 μg/g fresh weight (fw) in trials carried out in the USA and in 
Germany (EPA, 2000; Nguyen and Jehle, 2007). In comparison, the levels of Cry1Ab protein ranged 
in young leaf tissue from 7.59 to 10.34 μg/g fw, in forage from 3.65 to 9.23 μg/g fw and in grain from 
0.19 to 0.69 μg/g fw (EFSA, 2009a). Székács et al. (2010) reported similar Cry1Ab levels [after 
allowance for the dry weight (dw) basis of analysis] in pollen to be 0.47 μg/g dw: levels in other 
tissues were approximately 17 μg/g dw in leaves, 5 μg/g dw in roots and 0.8 μg/g dw in grain. 
3. Comparative analysis of MON 810 
Pollen analysis forms part of the comparative assessment of a crop’s agronomic and phenotypic 
characteristics. 
With regard to the comparative compositional analysis, no guidance exists for the compositional 
analysis of pollen (e.g., OECD consensus documents detailing recommendations for key 
compositional parameters for new plant varieties). Moreover, only a limited number of data are 
available with regard to the composition of maize pollen collected from the plant as such (Pfahler and 
Linskens, 1970, 1971, 1973; Ceska and Styles, 1984; Bianchi et al., 1990; Anaya et al., 1992) and 
pollen collected by bees [reviewed by Roulston and Cane (2000) and Campos et al. (2008)].  
To date, the Panel has not seen the need for specific data on pollen composition and has presumed 
compositional similarity provided that experimental data confirm similarity in other maize tissues (i.e. 
grains and forage).  
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3.1. Agronomic and phenotypic characteristics 
The agronomic and phenotypic characteristics of maize MON 810 in relation to appropriate non-GM 
maize control materials having a comparable genetic background have been assessed by the EFSA 
GMO Panel in connection with the renewal applications for food and feed use and cultivation of maize 
MON 810 (EFSA, 2009a), as well as in connection with the assessment of several stacked GM maize 
events (EFSA, 2005a,b,c,d,e, 2009b). It was concluded that maize MON 810 is agronomically and 
phenotypically equivalent to currently grown non-GM maize varieties, with the exception of the insect 
resistance conferred by the Cry1Ab protein (EFSA, 2009a). In particular, pollen production and 
viability remained unchanged in maize MON 810 relative to its comparator (EFSA, 2009a).  
3.2. Composition 
The previous safety assessment of maize MON 810 included an extensive comparative compositional 
assessment of forage and grains from MON 810 and from its conventional counterpart, showing that 
there were no biologically relevant compositional differences between maize MON 810 and its 
comparator, except for the introduced traits (EFSA, 2009a).  
4. Safety of Cry1Ab protein for human health 
The EFSA GMO Panel has previously assessed the safety of the Cry1Ab protein in MON 810 and did 
not identify concerns regarding potential toxicity and allergenicity. The results of the molecular 
characterisation indicate that the same Cry1Ab protein is expressed in pollen as in other parts of the 
plant (EFSA, 2009a). Therefore the assessment and conclusions of the GMO Panel on safety of the 
protein Cry1Ab, including toxicity and allergenicity, reached for food/feed aspects (EFSA, 2009a) 
also apply to pollen. In addition, as mentioned above, the levels of Cry1Ab in pollen were lower than 
in grains and the other tissues analysed. 
5. Safety of MON 810 pollen for human health 
As only limited data are available on the compositional and safety characteristics of maize pollen in 
general, and of pollen of maize MON 810 in particular, the EFSA GMO Panel considered a range of 
data constituting a weight-of-evidence approach for the safety of maize MON 810 pollen compared 
with other maize pollen. These data consisted of: 
1. The above-mentioned molecular characterisation of maize MON 810; 
2. The extensive data on composition and agronomic/phenotypic characteristics of maize 
MON810, including reproductive traits related to pollen production and viability; 
3. The safety of the Cry1Ab protein, as expressed in maize MON 810. 
As no concerns have thus been identified over the safety of maize MON 810 relative to that of non-
GM maize, the EFSA GMO Panel considers it unlikely that the replacement of non-GM maize pollen 
with maize MON 810 pollen would raise additional safety issues. 
6. Conclusion 
While the EFSA GMO Panel is not in a position to conclude on the safety of maize pollen in or as 
food in general, it concludes that the genetic modification in maize MON 810 does not constitute an 
additional health risk if maize MON 810 pollen were to replace maize pollen from non-GM maize in 
or as food. 
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DOCUMENTATION PROVIDED TO EFSA 
1. Letter from the Competent Authority of the Netherlands, received on 15 March 2012, concerning 
a request for placing on the market of pollen MON 810 in the European Union in accordance with 
Regulation (EC) No 1829/2003. 
2. Acknowledgement letter, dated 3 April 2012, from EFSA to the Competent Authority of The 
Netherlands (Ref. PB/KL/EW/sm (2012) out-6472368). 
3. Letter from EFSA to the applicant, dated 25 April 2012, requesting additional information under 
completeness check (Ref. KL/EW/CE/sm (2012) out-6513991). 
4. Letter from the applicant, received on 14 May 2012, providing additional information under 
completeness check. 
5. Letter from EFSA to the applicant, dated 29 May 2012, delivering the “Statement of Validity” for 
application EFSA-GMO-NL-2012-107, pollen MON 810 submitted by Monsanto Europe 
S.A./N.V. under Regulation (EC) No 1829/2003 (Ref. KL/EW/sm (2012) out-6602627). 
6. Letter from the applicant, received on 4 June 2012, providing EFSA with an updated version of 
the application EFSA-GMO-NL-2012-107 submitted by Monsanto Europe S.A./N.V. under 
Regulation (EC) No 1829/2003. 
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